Translation. Region: Russian Federation –
Source: People's Republic of China in Russian – People's Republic of China in Russian –
An important disclaimer is at the bottom of this article.
Source: People's Republic of China – State Council News
Chengdu, March 21 (Xinhua) — French pharmaceutical giant Sanofi recently officially opened an innovation and operations center in Chengdu, southwest China's Sichuan Province, marking the company's first such facility in China and signaling its expanding presence in the country.
The decision to establish the center in Chengdu reflects the company's commitment to always be at the forefront of global innovation, said Madeleine Roach, executive vice president of business operations at Sanofi.
According to her, Chengdu's significant position in the biopharmaceutical industry, its rich talent pool, and its vibrant innovation ecosystem make it an ideal location to expand Sanofi's capabilities and deepen its presence in China. She is convinced that this development will benefit both patients and the company's partners.
The new center's activities will cover a wide range of activities, from R&D and clinical trials to supply chain management services, and it is planned to create more than 600 professional positions by the end of 2026.
According to the company, the Chengdu center has already established cooperation with Sanofi's operational centers in countries such as India, Hungary, Malaysia, Colombia, and Spain, forming an efficient, interconnected global network.
Paris-headquartered Sanofi first entered the Chinese market in 1982, opening a local office. Since then, the company has steadily expanded its innovation and research activities in China. It currently has several manufacturing and R&D centers in China, including four R&D centers in Shanghai, Beijing, Chengdu, and Suzhou.
In 2025, the company began construction of a new insulin active pharmaceutical ingredient production base in Beijing with a total investment of €1 billion (approximately $1.16 billion). -0-
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.